book review
Books reviews on workplace, corporate, and business driven books.
Understanding Sickle Cell Disease: Disparities and Opportunities for Better Care
Introduction: Starting life with sickle cell disease poses challenges, especially for babies born in disadvantaged areas. A recent study, presented at the American Society of Hematology's annual meeting, sheds light on significant findings regarding the prevalence and social factors associated with sickle cell disease births. Key Findings: Disadvantaged Areas and Births: Almost two-thirds of babies born with sickle cell disease come from disadvantaged areas, revealing a concerning link between socio-economic conditions and the prevalence of this genetic blood disorder. State Disparities: The study uncovers wide variations among states in the rate of sickle cell disease births in areas with crowded housing and limited transportation options. Public Health Implications: Researchers emphasize the importance of using this data to guide public health efforts in supporting the complex needs of children with sickle cell disease and their families. Treatment Disparities: Underused Treatments: The study highlights the underuse of evidence-based treatments like antibiotics and hydroxyurea, which can significantly reduce symptoms but are not widely prescribed. Gene Editing vs. Conventional Treatments: While gene-editing treatments for sickle cell disease gain attention, the under-prescribing of more affordable conventional drugs receives less focus, even though these treatments can be highly effective. Impact on Health and Society: Uncontrolled symptoms can lead to frequent emergency department visits, affecting school attendance, employment, mental health, and social relationships. Demographic Insights: Racial Disparities: Sickle cell disease affects 1 in every 350 Black and non-Hispanic babies, with 90% of children born with the disease being Black. Prevalence of Sickle Cell Anemia: More than half (57%) of children born with sickle cell disease have sickle cell anemia, causing the most debilitating symptoms. Social Vulnerability Index (SVI): The study uses the CDC's SVI to assess county-level social vulnerability, revealing higher sickle cell birth rates in areas with high SVI scores. Michigan's Role in the Study: Researcher's Perspective: Sarah Reeves, a University of Michigan epidemiologist, played a crucial role in the study, examining Michigan's sickle cell population and the care they receive. Local Efforts: Reeves collaborated with the Michigan Department of Health and Human Services to identify individuals with sickle cell disease and ensure they have access to necessary health care coverage. Underused Treatments in Michigan: The study indicates that even in Michigan, there is underuse of antibiotics and hydroxyurea, highlighting the need for improved awareness and access to these treatments. Conclusion: The study provides essential insights into the rates and variations in sickle cell disease births, emphasizing the impact of social vulnerability. It calls for increased attention to evidence-based treatments, addressing disparities in care, and focusing on public health initiatives to support affected children and their families. In moving forward, the findings stress the importance of collaborative efforts between researchers, healthcare providers, and policymakers to bridge gaps in care and ensure that all children, regardless of socio-economic background, receive the necessary support and treatments for sickle cell disease.The coverage is part of the Children's Special Health Care Services insurance program but since late 2021 has covered adults with sickle cell disease too.She and her colleagues have also shown the vast underuse of antibiotics and hydroxyurea nationally in previously published studies, as well as the underuse of transcranial Doppler ultrasound scans to detect constricted flow in the arteries supplying the brain, which can predict stroke risk.Reeves collaborated with the Michigan Department of Health and Human Services to identify individuals with sickle cell disease and ensure they have access to necessary health care coverage.More than half (57%) of children born with sickle cell disease have sickle cell anemia, causing the most debilitating symptoms.Gene Editing vs. Conventional Treatments: While gene-editing treatments for sickle cell disease gain attention, the under-prescribing of more affordable conventional drugs receives less focus, even though these treatments can be highly effective. Summary. A recent study presented at a medical meeting revealed that nearly two-thirds of babies born with sickle cell disease come from disadvantaged areas. This means that babies starting life with this genetic blood disorder often face additional challenges. The study also found differences among states in the rates of sickle cell disease births, emphasizing the impact of crowded housing and limited transportation options in certain areas.Researchers suggest that understanding these findings can help public health authorities better support children with sickle cell disease and their families. The study highlights the underuse of effective treatments, like antibiotics and hydroxyurea, which can ease symptoms but aren't widely prescribed.The research focused on the Social Vulnerability Index (SVI) to assess areas with higher vulnerability, revealing that sickle cell birth rates were higher in these places. Michigan played a key role in the study, with efforts to understand the state's sickle cell population and improve access to healthcare coveragethe study calls for increased attention to evidence-based treatments, addressing disparities, and supporting public health initiatives to assist children with sickle cell disease and their families. Bridging these gaps requires collaboration among researchers, healthcare providers, and policymakers to ensure all children receive necessary care, regardless of their background.
By Nadeem Saifi3 years ago in Journal
Michael Strahan's Daughter Faces Medulloblastoma: Understanding the Journey
For the past couple of months, Michael Strahan's 19-year-old daughter, Isabella, has been courageously battling medulloblastoma, a type of brain tumor. Isabella, a freshman at the University of Southern California, received her diagnosis in October after an MRI scan revealed the presence of this cancerous and fast-growing tumor in the cerebellum – the part of the brain responsible for movement and coordination. In a recent interview on "Good Morning America," Michael and Isabella Strahan shared their decision to go public with Isabella's health struggles, hoping to shed light on her journey and potentially help others facing similar challenges. Isabella, a model with recent campaigns alongside Sephora, expressed her desire not to "hide" her cancer journey. She underwent brain surgery in late October, followed by rehabilitation and a six-week radiation treatment. The next phase involves a chemotherapy regimen led by doctors at Duke University, where her twin sister Sophia is a freshman. Isabella sees her platform as an opportunity to be a voice for those undergoing similar experiences. She aims to provide support and encouragement for individuals enduring chemotherapy or radiation, sharing snippets of her daily life to bring a sense of connection. Beyond being a source of hope, Isabella's openness may draw attention to the need for increased funding for brain tumor treatment, particularly in the realm of pediatric cases. Dr. David Ashley, a neuro-oncologist and director of Duke University's Preston Robert Tisch Brain Tumor Center, emphasizes the importance of this moment in history, noting the availability of tools and therapies to make a significant impact. Understanding Medulloblastoma: Five Key Questions Who is Affected by Medulloblastoma? Medulloblastoma primarily impacts children between the ages of 5 and 9. However, it can be diagnosed in individuals of all ages. While some may have genetic predispositions, Isabella Strahan's case, like many others, is akin to a "lightning strike." Tumors often emerge from precursor cells in the brain, possibly developing before or around birth. Medulloblastoma is the most common malignant brain tumor in childhood, constituting about 20% of all cases. What are the Symptoms of Medulloblastoma? Due to its location in the back of the brain, symptoms of medulloblastoma can include clumsiness, difficulty walking, fatigue, changes in vision and hearing, and alterations in basic skills like handwriting. Headaches, especially if persistent, associated with vomiting or changes in behavior, can also be indicative. While this cancer is rare and fast-growing, routine imaging is not recommended. Instead, prompt medical attention is advised for new headaches or other neurological symptoms. How is Medulloblastoma Treated? The typical treatment path involves surgery to remove the tumor, followed by radiation and chemotherapy. The specifics vary based on factors like tumor location, type, and whether it has spread. Each patient's treatment plan is tailored accordingly. Isabella's Journey: A Beacon of Strength Isabella Strahan's decision to share her journey serves as an inspiration for others. Her resilience through brain surgery, rehabilitation, and radiation, with chemotherapy on the horizon, highlights the strength needed to face such challenges. Isabella's openness not only provides a sense of camaraderie for those undergoing similar treatments but also emphasizes the importance of awareness and support for brain tumor research. The Need for Funding and Advances in Treatment Dr. David Ashley underscores the critical juncture in brain tumor research. While advancements in understanding the molecular biology of these tumors exist, he emphasizes the need for resources to translate this knowledge into targeted therapies and immunotherapies. Increased funding is essential for developing more effective treatment options, especially for pediatric cases. In the face of adversity, Isabella Strahan's journey becomes a call to action – a reminder of the importance of support, awareness, and continued research to improve outcomes for those battling medulloblastoma.Just as with treatment, a person's prognosis for surviving medulloblastoma depends on several factors, including the molecular group, as well as the patient's age and whether the tumor has spread. More than 70% of people survive five years past their diagnosis and beyond, according to the National Cancer Institute. Children under the age of 3 diagnosed with medulloblastoma may have lower survival rates because the treatment options for that age group are limited, according to Ashley. Brain tumors are the most common cause of cancer-related deaths in childhood, and they cause enormous emotional and financial strain on families," Ashley said. "We've got to do better at the treatments, which are inadequate. We do cure a lot of kids with brain tumors, but at the moment, many of those children are going to need radiation and chemotherapy, and that's not right. We shouldn't be doing that."
By Nadeem Saifi3 years ago in Journal
Unlocking New Avenues in Cancer Treatment: Targeting MYC with NT-B2R Peptide Library
Introduction Scientists have made a groundbreaking discovery in cancer research by developing a peptide library that could pave the way for targeting the elusive cancer factor, MYC. MYC is a crucial transcription factor associated with many human cancers, but due to its disordered nature and rapid turnover rate, it has been a challenging target for oncology therapies. The Breakthrough: NT-B2R Peptide In a recent study, researchers reported the development of NT-B2R, a MYC-targeted peptide derived from a molecular library. This library, created using a stereo-diversified bicyclic peptide approach, explores a three-dimensional chemical space previously unexplored with conventional constructs. Library Development Process Cyclization using ROM-RCM Reaction: The library was cyclized in one step using the ROM-RCM reaction, resulting in a bicyclic peptide that could be easily linearized for sequencing through a one-step deallylation process. Proline Scanning with FIVAL Model: Proline residues were strategically introduced to favor preferred conformations, aiding in the development of bicyclic structures. Racemic exo- and endo-norbornene building molecules were used for "proline scanning" using the FIVAL model peptide sequence. Validation and Screening: The developed library underwent validation through tetrazine assessment, Edman degradation, mass spectrometry, and molecular simulations. A total of 42 beads were randomly selected, sequenced, and linearized. The resulting NT-B peptide library was then screened for MYC-binding molecular hits. Evaluation of Binding Efficiency ELISA Assays: Racemic exo- and endo-norbornene isomer combinations were evaluated for their binding efficiency to recombinant MYC using enzyme-linked immunosorbent assays (ELISA). Competitive ELISA: Racemic NT-B2-Exo and NT-B2-Endo isomers were generated and assessed for their MYC-binding affinities through competitive ELISA. Temperature-Based Circular Dichroism Spectroscopy: This method was employed to investigate the mechanisms underlying the NT-B2-MYC interactions. Cellular Impact and Therapeutic Potential Cellular Thermal Shifting Experiments: NT-B2R demonstrated the ability to bind to MYC in complex biological settings, as demonstrated through cellular thermal shifting experiments on U87 cellular lysates. Suppression of MYC Transcription Activities: NT-B2R effectively suppressed MYC transcription activities and cell proliferation, indicating its potential as a therapeutic agent. RNA-Seq Analysis: RNA-seq analysis of U87 cells treated with NT-B2R revealed considerable transcriptomic alterations, with 1,322 genes increased and 704 genes decreased, aligning with MYC's role as a master transcription factor. Molecular Insights and Stability Molecular Simulations: Atomistic molecular simulations unveiled that all eight isomers acquired stable conformations during the simulation time, with unique ring pucker orientations. Binding Affinities: Library screening generated eight hits with micromolar-level binding affinities to MYC, further validated through protein thermal shift assays. Isomer Stability: NT-B2R production yielded two isomers with different retention durations. Molecular simulations revealed that NT-B2R had higher stability than NT-B2S due to fewer conformations and higher inner-ring forces. Therapeutic Implications Impact on MYC Activities: NT-B2R bound to MYC resulted in reduced metabolic activities and propagation in U87 cell lines without affecting MYC production and phosphorylation. Transcriptomic Alterations: The therapy induced significant transcriptomic alterations, showcasing its potential in altering gene expression patterns associated with MYC. In conclusion, the development of the NT-B2R peptide library represents a significant leap in targeting the challenging MYC factor. With its demonstrated effectiveness in suppressing MYC activities and inducing transcriptomic alterations, NT-B2R opens new possibilities for the development of clinically viable therapeutics in oncology. This breakthrough brings hope for more effective cancer treatments in the future.The developed library underwent validation through tetrazine assessment, Edman degradation, mass spectrometry, and molecular simulations. A total of 42 beads were randomly selected, sequenced, and linearized. The resulting NT-B peptide library was then screened for MYC-binding molecular hits.that could pave the way for targeting the elusive cancer factor, MYC. MYC is a crucial transcription factor associated with many human cancers, but due to its disordered nature and rapid turnover rate, it has been a challenging target for oncology therapies.tetrazine assessment, Edman degradation, mass spectrometry, and molecular simulations. A total of 42 beads were randomly selected, sequenced, and linearized. The resulting NT-B peptide library was then screened for MYC-binding molecular hits.assessed for their MYC-binding affinities through competitive ELISA.induced significant transcriptomic alterations, showcasing its potential in altering gene expression patterns associated with MYC.
By Nadeem Saifi3 years ago in Journal
2024 SAG Awards Nominations: A Snapshot of Excellence in Film and Television
Motion Picture Highlights The excitement is palpable as the 2024 Screen Actors Guild (SAG) Awards nominations have been unveiled, showcasing a diverse array of outstanding performances in both film and television. Among the motion picture nominees, Christopher Nolan's "Oppenheimer" and the unexpected yet intriguing "Barbie" lead the pack with four nominations each, including a nod in the coveted Best Cast category. Oppenheimer and Barbie Shine Bright in Best Cast Category "Oppenheimer" and "Barbie" stand shoulder to shoulder in the Best Cast category, demonstrating their ensemble excellence. Notably, "Barbie" secures a stunt performance nomination, making it the sole film in this year's lineup to achieve such recognition. Individual Brilliance: Oppenheimer Dominates Acting Categories Cillian Murphy, the charismatic lead of "Oppenheimer," earns a well-deserved nomination for Best Actor, while Robert Downey Jr. and Emily Blunt shine in the Supporting Actor and Supporting Actress categories, respectively. This film's multiple nominations underline its prowess not only as a collective effort but also in individual performances. Barbie's Diverse Recognition "Barbie" isn't just about dolls and play—it's a film that has Margot Robbie nominated for Best Actress and Ryan Gosling for Best Supporting Actor. This unexpected yet intriguing combination showcases the film's ability to captivate audiences on various fronts. Killers of the Flower Moon and American Fiction: Strong Contenders Joining the Best Cast nominees are "Killers of the Flower Moon" and "American Fiction," each receiving three nominations. Lily Gladstone from "Killers" earns a nod for Best Actress, while Robert De Niro is recognized in the Best Supporting Actor category. Jeffrey Wright and Sterling K. Brown from "American Fiction" add to the film's impressive nominations tally. The Color Purple and Other Contenders Danielle Brooks from "The Color Purple" secures a well-deserved nomination for Best Supporting Actress. Other films earning dual nominations include "Nyad," "The Holdovers," "Poor Things," and "Maestro," showcasing the diverse and rich talent pool in this year's SAG Awards. Television Highlights As the film nominees promise a night of intense competition, the television categories add their own flavor to the mix. HBO's "Succession" takes the lead with five nominations, including the prestigious Best Ensemble in a Drama Series. Drama Ensembles: A Power Play Competing for the Best Drama Ensemble award are "Succession," "The Crown," "The Gilded Age," "The Last of Us," and "The Morning Show." The latter two also vie for additional awards, with "The Morning Show" earning nominations for Billy Crudup and Jennifer Aniston in Best Actor and Actress in a Drama Series, respectively. Ted Lasso and The Bear Bring Laughter In the comedy categories, "Ted Lasso" and "The Bear" steal the spotlight with four nominations each. Both shows secure Best Comedy Series Ensemble nods, standing alongside "Abbott Elementary," "Barry," and "Only Murders in the Building." Limited Series Excellence: Beef Takes the Stage The limited series "Beef" showcases the talents of Steven Yeun and Ali Wong, both receiving nominations for their roles. The series also lands a nod in the Stunt Ensemble Performance category, adding an extra layer of excitement. Issa Rae and Kumail Nanjiani: Dynamic Announcers The SAG Awards nominations were announced by the dynamic duo of Issa Rae and Kumail Nanjiani on Instagram Live, bringing a fresh and engaging approach to the unveiling of this year's honorees. Nanjiani's humor and Rae's double nomination moment added a delightful touch to the announcement. Save the Date: 30th Annual SAG Awards Mark your calendars for the 30th annual SAG Awards, set to air live on Netflix on February 24 at 5 p.m. PT/8 p.m. ET from the iconic Shrine Auditorium in Los Angeles. As anticipation builds, audiences eagerly await to see which stars will shine the brightest on this celebrated night of recognition. In conclusion, the 2024 SAG Awards promise a thrilling celebration of talent, with "Oppenheimer" and "Barbie" leading the film nominations and "Succession" dominating the television categories. As we count down the days to the awards ceremony, the world is poised to witness exceptional performances and unforgettable moments in the world of entertainment.On the TV side, Succession leads with five nods, including one for best ensemble in a drama series. Its fellow best drama ensemble nominees are The Crown, The Gilded Age, The Last of Us and The Morning Show.In addition to the drama ensemble award, The Morning Show and The Last of Us are each up for two more awards. The Morning Show‘s Billy Crudup and Jennifer Aniston are nominated for best actor and actress, respectively, in a drama series. The Last of Us‘ Pedro Pascal and Bella Ramsey are nominated for best actor and actress, respectively, in a drama seriesTed Lasso and The Bear scored four nominations across the comedy categories, including best comedy series ensemble nods for both
By Nadeem Saifi3 years ago in Journal
The Soft Touch Suede Jacket's Elegant Appeal: A Style Guide. Content Warning.
Certain classic pieces stand out in the ever-changing world of fashion for their enduring appeal and varied style. Among these, the soft touch suede jacket stands out for its perfect balance of elegance and comfort. We'll look at the allure of the suede jacket and how to fit it into your wardrobe for a smart and professional look in this style guide.
By Angelina Johnson3 years ago in Journal
The Crown of Gilded Bones
"The Crown of Gilded Bones" is a fantasy novel by Jennifer L. Armentrout, the third book in her "Blood and Ash" series. This continuation of the story is rich with fantasy, romance, and political intrigue, as it follows the journey of Poppy, the protagonist, and her partner, Casteel. The novel blends elements of high fantasy with emotional depth, exploring themes of power, identity, and love.
By RAMESHKUMAR S3 years ago in Journal
Deep Sleep Diabetes Remedy: 3-Minute Bedtime Ritual Reverses Type 2 Diabetes as You Sleep
Deep Sleep Diabetes Remedy Review - Is It Worth The Cost? Deep Sleep Diabetes Remedy: 3-Minute Bedtime Ritual Reverses Type 2 Diabetes as You Sleep ( Deep Sleep Diabetes Remedy: Review the Tea Ingredients Book)
By Bar Brothers System3 years ago in Journal
Taylor Swift Shattered Las Vegas Ticket Sales Records in 2023
Taylor Swift’s 2023 Las Vegas residency, "Barrystickets.com," rewrote the city's entertainment history, obliterating ticket sales records and affirming her status as a music phenomenon. Las Vegas, renowned for its star-studded residencies, witnessed an unprecedented frenzy as fans clamored to witness Swift's electrifying performances in a setting renowned for its intimacy and spectacle.
By Aurang Zeb3 years ago in Journal
Taylor Swift Shattered Las Vegas Ticket Sales Records in 2023
Taylor Swift’s 2023 Las Vegas residency, "Shattered," rewrote the city's entertainment history, obliterating ticket sales records and affirming her status as a music phenomenon. Las Vegas, renowned for its star-studded residencies, witnessed an unprecedented frenzy as fans clamored to witness Swift's electrifying performances in a setting renowned for its intimacy and spectacle.
By Aurang Zeb3 years ago in Journal
